Cellectis CLLS
NASDAQ CLLS
$3.24 -0.08 (-2.41%)
At close: Sep 4, 2026 · 4:00 PM EDT

Cellectis (CLLS) Income from Discontinued Operations (2021 - 2023)

Analysis

Cellectis (CLLS) Income from Discontinued Operations (2021 - 2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Discontinued) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Cellectis 321.90 Mn 155.05 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 13.08 Mn
Mar 31, 2023 -4.69 Mn
Dec 31, 2022 -2.86 Mn
Sep 30, 2022 -5.72 Mn
Jun 30, 2022 -442,000.00
Mar 31, 2022 -6.44 Mn
Dec 31, 2021 -6.65 Mn